IO Biotech Reports Clinical Improvement in PFS from Phase 3 Trial of Cylembio + KEYTRUDA in Advanced Melanoma- Narrowly Misses Statistical Significance
DENVER, Colo., Aug 11, 2025 (247marketnews.com)- IO Biotech (NASDAQ:IOBT) reported topline results from its pivotal Phase 3 trial evaluating Cylembio...
